-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
MaxCyte, Inc. (NASDAQ:MXCT) Shares Sold by River & Mercantile Asset Management LLP
MaxCyte, Inc. (NASDAQ:MXCT) Shares Sold by River & Mercantile Asset Management LLP
River & Mercantile Asset Management LLP trimmed its stake in MaxCyte, Inc. (NASDAQ:MXCT – Get Rating) by 13.1% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,100,000 shares of the company's stock after selling 315,500 shares during the quarter. MaxCyte comprises about 1.9% of River & Mercantile Asset Management LLP's holdings, making the stock its 7th biggest position. River & Mercantile Asset Management LLP owned 2.07% of MaxCyte worth $14,849,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other large investors have also bought and sold shares of the stock. BlackRock Inc. grew its holdings in shares of MaxCyte by 4.4% during the first quarter. BlackRock Inc. now owns 5,443,837 shares of the company's stock valued at $38,052,000 after buying an additional 229,373 shares during the last quarter. Vitruvian Partners LLP grew its holdings in shares of MaxCyte by 31.7% during the first quarter. Vitruvian Partners LLP now owns 4,385,670 shares of the company's stock valued at $30,656,000 after buying an additional 1,055,670 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of MaxCyte by 4.0% during the first quarter. Vanguard Group Inc. now owns 3,284,596 shares of the company's stock valued at $22,958,000 after buying an additional 126,906 shares during the last quarter. Massachusetts Financial Services Co. MA grew its holdings in shares of MaxCyte by 2.8% during the first quarter. Massachusetts Financial Services Co. MA now owns 1,872,197 shares of the company's stock valued at $13,087,000 after buying an additional 51,392 shares during the last quarter. Finally, American Century Companies Inc. acquired a new position in shares of MaxCyte during the first quarter valued at about $11,583,000. 66.40% of the stock is currently owned by institutional investors and hedge funds.
Get MaxCyte alerts:Analyst Upgrades and Downgrades
Separately, BTIG Research boosted their price target on shares of MaxCyte from $10.00 to $11.00 and gave the stock a "buy" rating in a report on Sunday, August 14th.
MaxCyte Stock Down 3.1 %
MaxCyte stock traded down $0.20 during midday trading on Tuesday, hitting $6.31. 4,625 shares of the stock were exchanged, compared to its average volume of 447,467. MaxCyte, Inc. has a 52-week low of $3.36 and a 52-week high of $16.28. The company has a market capitalization of $642.74 million, a PE ratio of -31.10 and a beta of 1.17. The stock's 50-day simple moving average is $5.43.Insider Buying and Selling
In related news, major shareholder Casdin Partners Master Fund, L sold 3,235,548 shares of the business's stock in a transaction dated Friday, July 1st. The shares were sold at an average price of $4.30, for a total transaction of $13,912,856.40. Following the transaction, the insider now directly owns 10,735,786 shares in the company, valued at $46,163,879.80. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 5.11% of the stock is owned by corporate insiders.
About MaxCyte
(Get Rating)
MaxCyte, Inc, a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.
Recommended Stories
- Get a free copy of the StockNews.com research report on MaxCyte (MXCT)
- The Two Things You Need To Know About Oracle's FQ1 Report
- Three Value Stocks For A Volatile Market
- 3 Energy Stocks Nearing Breakouts From Cup-Shaped Patterns
- Do These Dividend Achievers Deserve A Place In Your Portfolio?
- Darden Restaurants Takes the Low Road Against Inflation
Receive News & Ratings for MaxCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MaxCyte and related companies with MarketBeat.com's FREE daily email newsletter.
River & Mercantile Asset Management LLP trimmed its stake in MaxCyte, Inc. (NASDAQ:MXCT – Get Rating) by 13.1% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,100,000 shares of the company's stock after selling 315,500 shares during the quarter. MaxCyte comprises about 1.9% of River & Mercantile Asset Management LLP's holdings, making the stock its 7th biggest position. River & Mercantile Asset Management LLP owned 2.07% of MaxCyte worth $14,849,000 as of its most recent filing with the Securities and Exchange Commission.
River&Mercantile Asset Management LLP根据其最近提交给美国证券交易委员会的Form 13F文件,在第一季度将其在MaxCyte,Inc.(纳斯达克代码:MXCT-GET Rating)的股份削减了13.1%。该公司在本季度出售了315,500股票后,拥有2,100,000股公司股票。Maxcell约占River&Mercantile Asset Management LLP所持股份的1.9%,使该股成为其第七大持仓。截至最近提交给美国证券交易委员会的文件,River&Mercantile Asset Management LLP拥有MaxCyte 2.07%的股份,价值14,849,000美元。
A number of other large investors have also bought and sold shares of the stock. BlackRock Inc. grew its holdings in shares of MaxCyte by 4.4% during the first quarter. BlackRock Inc. now owns 5,443,837 shares of the company's stock valued at $38,052,000 after buying an additional 229,373 shares during the last quarter. Vitruvian Partners LLP grew its holdings in shares of MaxCyte by 31.7% during the first quarter. Vitruvian Partners LLP now owns 4,385,670 shares of the company's stock valued at $30,656,000 after buying an additional 1,055,670 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of MaxCyte by 4.0% during the first quarter. Vanguard Group Inc. now owns 3,284,596 shares of the company's stock valued at $22,958,000 after buying an additional 126,906 shares during the last quarter. Massachusetts Financial Services Co. MA grew its holdings in shares of MaxCyte by 2.8% during the first quarter. Massachusetts Financial Services Co. MA now owns 1,872,197 shares of the company's stock valued at $13,087,000 after buying an additional 51,392 shares during the last quarter. Finally, American Century Companies Inc. acquired a new position in shares of MaxCyte during the first quarter valued at about $11,583,000. 66.40% of the stock is currently owned by institutional investors and hedge funds.
其他一些大型投资者也买入和出售了该股的股票。今年第一季度,贝莱德持有的MaxCyte股票增加了4.4%。贝莱德股份有限公司现在持有该公司5,443,837股股票,价值38,052,000美元,该公司在上个季度又购买了229,373股。今年第一季度,维特鲁维亚合伙公司对MaxCyte股票的持有量增加了31.7%。在上个季度又购买了1,055,670股后,维特鲁安合伙公司现在拥有4,385,670股该公司的股票,价值30,656,000美元。先锋集团(Vanguard Group Inc.)第一季度增持MaxCyte股票4.0%。先锋集团目前持有该公司3,284,596股股票,价值22,958,000美元,上一季度又购买了126,906股。今年第一季度,马云持有的MaxCyte股票增加了2.8%。马云现在持有该公司1,872,197股股票,价值13,087,000美元。马云在上个季度又购买了51,392股。最后,美国世纪公司在第一季度收购了MaxCyte的新头寸,价值约11,583,000美元。66.40%的股票目前由机构投资者和对冲基金持有。
Analyst Upgrades and Downgrades
分析师升级和下调评级
Separately, BTIG Research boosted their price target on shares of MaxCyte from $10.00 to $11.00 and gave the stock a "buy" rating in a report on Sunday, August 14th.
另外,BTIG Research将MaxCyte的目标价从10.00美元上调至11.00美元,并在8月14日(星期日)的一份报告中给予该股“买入”评级。
MaxCyte Stock Down 3.1 %
Maxcell股票下跌3.1%
Insider Buying and Selling
内幕买卖
In related news, major shareholder Casdin Partners Master Fund, L sold 3,235,548 shares of the business's stock in a transaction dated Friday, July 1st. The shares were sold at an average price of $4.30, for a total transaction of $13,912,856.40. Following the transaction, the insider now directly owns 10,735,786 shares in the company, valued at $46,163,879.80. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 5.11% of the stock is owned by corporate insiders.
在相关新闻中,大股东Casdin Partners Master Fund,L在日期为7月1日星期五的交易中出售了3235548股该业务的股票。这些股票以4.30美元的平均价格出售,总成交金额为13,912,856.40美元。交易完成后,这位内部人士现在直接拥有该公司10,735,786股,价值46,163,879.80美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的,可以通过美国证券交易委员会网站访问该文件。5.11%的股份由企业内部人士持有。
About MaxCyte
关于MaxCyte
(Get Rating)
(获取评级)
MaxCyte, Inc, a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.
Maxcell,Inc.是一家全球生命科学公司,致力于下一代细胞疗法的发现、开发和商业化。其产品包括:Expert ATx,一种用于中小规模转基因的静态电穿孔仪器;Expert STx,一种用于蛋白质生产和药物开发的流动电穿孔设备,以及用于基于细胞分析的治疗靶点的表达;Expert GTx,一种用于治疗应用中大规模转基因的流动电穿孔设备;以及Expert VLx,用于超大规模细胞工程。
Recommended Stories
推荐故事
- Get a free copy of the StockNews.com research report on MaxCyte (MXCT)
- The Two Things You Need To Know About Oracle's FQ1 Report
- Three Value Stocks For A Volatile Market
- 3 Energy Stocks Nearing Breakouts From Cup-Shaped Patterns
- Do These Dividend Achievers Deserve A Place In Your Portfolio?
- Darden Restaurants Takes the Low Road Against Inflation
- 免费获取StockNews.com关于MaxCyte的研究报告(MXCT)
- 关于甲骨文的FQ1报告,你需要知道的两件事
- 波动市场的三只价值股
- 3个能源类股接近突破杯形格局
- 这些股息获得者值得在你的投资组合中占有一席之地吗?
- 达顿餐厅走低通胀之路
Receive News & Ratings for MaxCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MaxCyte and related companies with MarketBeat.com's FREE daily email newsletter.
接收MaxCyte日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对MaxCyte和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧